Galectin-3 in Kidney Diseases: From an Old Protein to a New Therapeutic Target - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Journal of Molecular Sciences Année : 2022

Galectin-3 in Kidney Diseases: From an Old Protein to a New Therapeutic Target

Résumé

Galectin-3 (Gal-3) is a 30KDa lectin implicated in multiple pathophysiology pathways including renal damage and fibrosis. Gal-3 binds β-galactoside through its carbohydrate-recognition domain. From intra-cellular to extra-cellular localization, Gal-3 has multiple roles including transduction signal pathway, cell-to-cell adhesion, cell to extracellular matrix adhesion, and immunological chemoattractant protein. Moreover, Gal-3 has also been linked to kidney disease in both preclinical models and clinical studies. Gal-3 inhibition appears to improve renal disease in several pathological conditions, thus justifying the development of multiple drug inhibitors. This review aims to summarize the latest literature regarding Gal-3 in renal pathophysiology, from its role as a biomarker to its potential as a therapeutic agent.

Dates et versions

hal-03838218 , version 1 (03-11-2022)

Identifiants

Citer

Louis Boutin, François Dépret, Etienne Gayat, Matthieu Legrand, Christos Chadjichristos. Galectin-3 in Kidney Diseases: From an Old Protein to a New Therapeutic Target. International Journal of Molecular Sciences, 2022, 23 (6), pp.3124. ⟨10.3390/ijms23063124⟩. ⟨hal-03838218⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More